Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading
A team of bioengineers from Tel Aviv University is currently developing a scaffold to help regenerate heart muscle through the use of autologous stem cells. The scientists, led by Dr. Tal Dvir, aim to replace damaged cardiac tissue in heart attack patients by creating a scaffold out of collagen and gold nanoparticles, and then infusing it with the patient’s own stem cells to stimulate the rejuvenation of cardiomyocytes. Continue reading
Researchers at the University Of Maryland School Of Medicine have created a pulmonary valve replacement for pediatric patients suffering from congenital heart conditions. The scientists, led by Dr. David L. Simpson, differentiated the patient’s own [autologous] stem cells into heart valvular cells and then arranged these cells to bioengineer a pulmonary valve that was unique to each patient. The valve was created in vitro [outside the body] so the next step would be to develop protocols to undertake clinical trials. Continue reading
- Pediatric Congenital Heart Disease patient
The Mayo Clinic recently announced the first stem cell based clinical trial for treating pediatric congenital heart disease in the US. The stem cell therapy seeks to treat hypoplastic left heart syndrome (HLHS), a rare defect in which the left side of the heart is critically underdeveloped. The treatment utilizes patient’s own [autologous] stem cells taken from the child’s umbilical cord blood.